[1] 国家卫生健康委办公厅. 关于印发新型抗肿瘤药物临床应用指导原则(2022年版)的通知国卫办医函(2022)465号[EB/OL]. [2022-12-30]. http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.
[2]

DARZALEX (Daratumumab) shows overall survival benefit and continued improvement in progression-free survival in patients with newly diagnosed multiple myeloma who are ineligible for transplant[EB/OL]. [2019-12-09]. https://www.jnj.com/darzalex-daratumumab-shows-overall-survival-benefit-and-continued-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-ineligible-for-transplant.
[3] 贾亚静, 刘辉, 王立茹, 等. 达雷妥尤单抗在复发难治性多发性骨髓瘤的应用[J]. 中华内科杂志, 2020, 59(5):347-352. doi:  10.3760/cma.j.cn112138-20191217-00821
[4] 路瑾. 达雷妥尤单抗治疗多发性骨髓瘤研究进展[J]. 中华血液学杂志, 2021, 42(3):260-264. doi:  10.3760/cma.j.issn.0253-2727.2021.03.016
[5] 赵莹, 王丽, 杨便红. 达雷妥尤单抗治疗复发难治性多发性骨髓瘤不良反应分析与护理[J]. 中国病案, 2021, 22(9):104-107.
[6] 田园, 朱美仙, 林圆圆, 等. 复发和难治性多发性骨髓瘤患者行达雷妥尤单抗单药治疗的护理[J]. 护理与康复, 2021, 20(6):93-96. doi:  10.3969/j.issn.1671-9875.2021.06.026
[7]

THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3):230-241. doi:  10.6004/jnccn.2020.0012